Biopharmaceutical company BioSpecifics Technologies Corp (NASDAQ:BSTC) stated on Friday its net income of USD2.7m (USD0.38 per basic share, USD0.37 per share on a fully diluted basis) for the third quarter ended 30 September 2017.
This marks a drop in earnings when compared with net income of USD3.1m (USD0.43 per basic share, USD0.42 per share on a fully diluted basis) for the same period in 2016.
Total revenues of USD6.5m were collected for the third quarter ended 30 September 2017, down over total revenue of USD6.9m for the same period in 2016.
Research and development expenses of USD0.4m were recorded for the third quarter ended 30 September 2017, a rise from R&D of USD0.3m for the same period in 2016.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government